sickrest.icu

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

Click To Continue Reading on Pulmonary Drugs Market

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma.

For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1285

Key Vendors:

Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

Tubeless insulin pump is a portable pump, which is effective in controlling blood glucose level. Advancements in technologies of insulin pumps, which reduce the need for daily insulin injection doses is expected to boost growth of the tubeless insulin pump market over the forecast period. Omnipod, by Insulet Corporation is expected to drive the growth of insulin pumps in near future. Omnipod is a novel tubeless insulin pump, which displays blood glucose levels, schedules insulin delivery, and calculates optimal insulin dosage based on food database. Furthermore, Insulet Corporation has recently added additional features such as touchscreen and Bluetooth to Omnipod Dash system. Portability offered by these devices permits easy attachment and placements of the device on clothing or desired body parts, which is expected to drive growth of the tubeless insulin pump market.

Click To Continue Reading on Tubeless Insulin Pump Market

Increasing funding by the government for studying various diseases including diabetes is also expected to fuel growth of the tubeless insulin pump market. For instance, in 2013, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) funded several important studies on different types of artificial pancreas devices to help patients suffering from type 1 and type 2 diabetes and gestational diabetes. Insulin pumps have gained traction, owing to the rapid acting mechanism offering instant insulin delivery, user friendly interface, and flexible insulin delivery, which is expected to fuel growth of the tubeless insulin pump market over the forecast period.

On the basis of geography, North America is expected to dominate the tubeless insulin pump market, followed by Europe, owing to high adoption rate for new technology and continuous government initiatives to create awareness regarding diabetes.

Increasing prevalence of diabetes due to obesity and increasing geriatric population is driving demand for tubeless insulin pump market. According to the World Health Organization, 2016, an estimated 422 million adults were suffering from diabetes globally. New technologies incorporated into tubeless insulin pump devices is leading to increasing demand for insulin pump devices worldwide. Market players are focused on developing new technologies in tubeless insulin pump devices, which can be used at home with ease and with accurate results, this in turn is expected to boost overall market growth during the forecast period. For instance, in 2016, in the U.K., Medtrum Technologies, Inc. launched S6 Easysense Disposable CGM System, which provides interstitial glucose levels in every two minutes and P6 Tubeless Patch Pump, which is ideal for type 2 diabetes management and gestational diabetes. It also allows monitoring of data using mobile app. However, high long-term cost associated with the use of tubeless insulin pump hampers the market growth. Compliance to therapy reduces over the time, owing to significant cost associated with daily use.

Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market.

Click To Continue Reading on Oncology Biosimilars Market

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3.